IDIOPATHIC CD4 LYMPHOPENIA
Clinical trials for IDIOPATHIC CD4 LYMPHOPENIA explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC CD4 LYMPHOPENIA trials appear
Sign up with your email to follow new studies for IDIOPATHIC CD4 LYMPHOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First-Ever treatment tested for mysterious immune deficiency
Disease control Recruiting nowThis study is testing whether a drug called belimumab is safe for people with idiopathic CD4 lymphopenia (ICL), a rare condition where the body has too few infection-fighting white blood cells. Twenty adults with ICL will receive belimumab through an IV over six months and be clo…
Matched conditions: IDIOPATHIC CD4 LYMPHOPENIA
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug aims to fortify the Body's defenses in rare immune disorder
Disease control Recruiting nowThis early-stage study is testing a new drug called NT-I7 (efineptakin alfa) to see if it is safe and can increase the number of a key type of immune cell (CD4 T cells) in people with idiopathic CD4 lymphopenia (ICL). ICL is a rare condition where people have very low levels of t…
Matched conditions: IDIOPATHIC CD4 LYMPHOPENIA
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC